{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T03:34:26Z","timestamp":1785641666174,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.prdoa.2020.100075","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T02:22:14Z","timestamp":1602901334000},"page":"100075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study"],"prefix":"10.1016","volume":"4","author":[{"given":"Andrew","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S.C.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Stell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Femia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Onuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prdoa.2020.100075_bb0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.50.2.318","article-title":"Parkinsonism: onset, progression, and mortality. 1967","volume":"50","author":"Hoehn","year":"1998","journal-title":"Neurology"},{"issue":"Suppl. 4","key":"10.1016\/j.prdoa.2020.100075_bb0010","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1353-8020(09)70831-4","article-title":"The clinical progression of Parkinson\u2019s disease","volume":"15","author":"Poewe","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"issue":"13","key":"10.1016\/j.prdoa.2020.100075_bb0015","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"issue":"Pt 11","key":"10.1016\/j.prdoa.2020.100075_bb0020","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","article-title":"Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study","volume":"123","author":"Schrag","year":"2000","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.prdoa.2020.100075_bb0025","first-page":"749","article-title":"A systematic review of the worldwide prevalence and incidence of Parkinson\u2019s disease","volume":"94","author":"Muangpaisan","year":"2011","journal-title":"J. Med. Assoc. Thail."},{"issue":"Suppl","key":"10.1016\/j.prdoa.2020.100075_bb0030","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2007.06.005","article-title":"The rationale for continuous dopaminergic stimulation in advanced Parkinson\u2019s disease","volume":"13","author":"Nyholm","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.prdoa.2020.100075_bb0035","first-page":"147","article-title":"Continuous intestinal infusion of levodopa\/carbidopa in advanced Parkinson\u2019s disease: efficacy, safety and patient selection","volume":"27","author":"Abbruzzese","year":"2012","journal-title":"Funct. Neurol."},{"issue":"5","key":"10.1016\/j.prdoa.2020.100075_bb0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ane.12733","article-title":"Algorithms for the treatment of motor problems in Parkinson\u2019s disease","volume":"136","author":"Dietrichs","year":"2017","journal-title":"Acta Neurol. Scand."},{"issue":"Suppl. 1","key":"10.1016\/j.prdoa.2020.100075_bb0045","first-page":"S13","volume":"14","year":"2011","journal-title":"Ann Indian Acad Neurol"},{"issue":"Suppl. 3","key":"10.1016\/j.prdoa.2020.100075_bb0050","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia","volume":"23","author":"Calabresi","year":"2008","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.prdoa.2020.100075_bb0055","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.prdoa.2020.100075_bb0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson\u2019s disease\u2014clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2020.100075_bb0065","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.prdoa.2020.100075_bb0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jns.2009.08.053","article-title":"Therapy adherence issues in Parkinson\u2019s disease","volume":"289","author":"Grosset","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.prdoa.2020.100075_bb0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/imj.13398","article-title":"Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia","volume":"47","author":"Williams","year":"2017","journal-title":"Intern. Med. J."},{"issue":"10","key":"10.1016\/j.prdoa.2020.100075_bb0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","article-title":"Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program","volume":"21","author":"Odin","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"12","key":"10.1016\/j.prdoa.2020.100075_bb0085","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","article-title":"Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach","volume":"34","author":"Antonini","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"16 Supplement","key":"10.1016\/j.prdoa.2020.100075_bb0090","article-title":"\u2018Advanced\u2019 Parkinson\u2019s disease characteristics in clinical practice: results from the OBSERVE-PD study, a cross-sectional observational study of 2615 patients (P6.001)","volume":"88","author":"Fasano","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.prdoa.2020.100075_bb0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","article-title":"Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients","volume":"19","author":"Fasano","year":"2019","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.prdoa.2020.100075_bb0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.prdoa.2020.100075_bb0105","series-title":"19th International Congress of Parkinson\u2019s Disease and Movement Disorders, San Diego, California","article-title":"Implemeting a Delphi panel to improve understanding of patient characteritics of advanced Parkinson\u2019s disease","author":"Antonini","year":"2015"},{"key":"10.1016\/j.prdoa.2020.100075_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41531-018-0046-4","article-title":"Objective measurement in routine care of people with Parkinson's disease improves outcomes","volume":"4","author":"Farzanehfar","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"issue":"Pt 6","key":"10.1016\/j.prdoa.2020.100075_bb0115","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/brain\/awq059","article-title":"Relationships between age and late progression of Parkinson\u2019s disease: a clinico-pathological study","volume":"133","author":"Kempster","year":"2010","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.prdoa.2020.100075_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189682","article-title":"Zappia, Factors influencing psychological well-being in patients with Parkinson\u2019s disease","volume":"12","author":"Nicoletti","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.prdoa.2020.100075_bb0125","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","article-title":"Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson\u2019s disease","volume":"19","author":"Muller","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2020.100075_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0891988717743589","article-title":"Predictors of mortality in nondemented patients with Parkinson disease: motor symptoms versus nonmotor symptoms","volume":"31","author":"Santos-Garcia","year":"2018","journal-title":"J. Geriatr. Psychiatry Neurol."}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112520300438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112520300438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:45:59Z","timestamp":1762911959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112520300438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":26,"alternative-id":["S2590112520300438"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2020.100075","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2020.100075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100075"}}